AstraZeneca (AZN) received the US Food and Drug Administration's approval for selumetinib to treat adults with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas, the agency said Wednesday.

A trial showed a 20% confirmed overall response rate in the selumetinib arm versus 5% for placebo, the agency said.

Safety findings were consistent with the known selumetinib safety profile, the FDA said.

Price: 89.44, Change: -0.11, Percent Change: -0.13